Redeye sees a soft Q2 report from Nanologica, which fell short of expectations on sales and showed a reversal in Syntagon profitability compared to Q1. Tangible progress among chromatography evaluation customers was disclosed but the market's focus on the thin cash position is likely behind the stocks plunge on the report.
LÄS MER
